The Effect of Glucagon-like Peptide-1 Receptor Agonists in Total Joint Arthroplasty: Implications, Complications, and Considerations
Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RAs) are used in diabetic patients for glycemic control. Yet, there has been a notable rise in their use for weight loss management in obese patients. This review critically appraises current evidence on perioperative implications of GLP-1 receptor agonists in TJA patients. The review discusses GLP-1 RA implications and use (physiology, pharmacology, pharmacodynamics, mechanisms of actions, and commonly used GLP-1 Ras), complications and adverse effects, considerations for the anesthesiologist, considerations for the TJA surgeon, and current clinical practice recommendations in 2025.
Authors
- Jason M. Jennings (ORCID: https://orcid.org/0000-0002-2047-783X)
- Douglas A. Dennis (ORCID: https://orcid.org/0000-0002-1803-5629)
- Kristen I. Barton
- Riley J. Boyle
Institutions
- Western University (CA)
- Colorado Joint Replacement (US)
- University of Tennessee at Knoxville (US)
Publication Details
- Journal
- Journal of the American Academy of Orthopaedic Surgeons
- Published
- 2026-09-01
- DOI
- https://doi.org/10.5435/jaaos-d-25-00892
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00